ATE338540T1 - Polyethyleneimine: dns-formulierungen für die aerosol-verabreichung - Google Patents

Polyethyleneimine: dns-formulierungen für die aerosol-verabreichung

Info

Publication number
ATE338540T1
ATE338540T1 AT00923636T AT00923636T ATE338540T1 AT E338540 T1 ATE338540 T1 AT E338540T1 AT 00923636 T AT00923636 T AT 00923636T AT 00923636 T AT00923636 T AT 00923636T AT E338540 T1 ATE338540 T1 AT E338540T1
Authority
AT
Austria
Prior art keywords
formulations
lipid
polyethylene imine
aerosol administration
dna formulations
Prior art date
Application number
AT00923636T
Other languages
English (en)
Inventor
Charles L Densmore Jr
Jack Vernon Knight
John Clifford Waldrep
Frank Mcnair Orson
Berma M Kinsey
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Application granted granted Critical
Publication of ATE338540T1 publication Critical patent/ATE338540T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT00923636T 1999-04-02 2000-03-31 Polyethyleneimine: dns-formulierungen für die aerosol-verabreichung ATE338540T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12757599P 1999-04-02 1999-04-02

Publications (1)

Publication Number Publication Date
ATE338540T1 true ATE338540T1 (de) 2006-09-15

Family

ID=22430807

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00923636T ATE338540T1 (de) 1999-04-02 2000-03-31 Polyethyleneimine: dns-formulierungen für die aerosol-verabreichung

Country Status (13)

Country Link
EP (1) EP1173224B1 (de)
JP (1) JP2002541125A (de)
KR (1) KR100707711B1 (de)
CN (1) CN1354678A (de)
AT (1) ATE338540T1 (de)
AU (1) AU770090B2 (de)
CA (1) CA2368185A1 (de)
DE (1) DE60030548T2 (de)
IL (1) IL145592A0 (de)
NZ (1) NZ514415A (de)
RU (1) RU2242970C2 (de)
WO (1) WO2000059548A1 (de)
ZA (1) ZA200107888B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150027A0 (en) * 1999-12-04 2002-12-01 Res Dev Foundation Carbon dioxide enhancement of inhalation therapy
DE19960206A1 (de) * 1999-12-14 2001-07-19 Frank Czubayko Komplexierung von RNS mit Polyethyleniminen zur deren Stabilisierung und zellulären Einschleusung
KR100401022B1 (ko) * 2000-12-11 2003-10-10 김도훈 항암제-폴리에틸렌이민 복합체 및 그의 제조방법
CA2437555A1 (en) * 2001-02-01 2002-08-08 Yiyu Zou Stabilised polymeric aerosols for pulmonary gene delivery
JP2005519129A (ja) * 2002-03-05 2005-06-30 クリーブランド ステート ユニバーシティー エアロゾル薬物送達のための凝集粒子
KR100764890B1 (ko) * 2005-11-14 2007-10-09 한국화학연구원 폴리에틸렌이민과 인지질을 접합하여 제조된 리포솜을이용한 항암주사제 및 이의 제조방법
US7700541B2 (en) * 2006-04-06 2010-04-20 Nitto Denko Corporation Biodegradable cationic polymers
US20130079382A1 (en) 2009-10-12 2013-03-28 Larry J. Smith Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
EP2338520A1 (de) 2009-12-21 2011-06-29 Ludwig Maximilians Universität Konjugat mit Zielfindungsligand und dessen Verwendung
EA201492055A1 (ru) * 2012-06-08 2015-11-30 Шир Хьюман Дженетик Терапис, Инк. ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ
BR112014029807A2 (pt) * 2012-06-08 2017-06-27 Ethris Gmbh administração pulmonar de rna mensageiro
BR102017016440A2 (pt) * 2017-07-31 2019-03-19 Universidade Federal Do Rio Grande Do Sul Composição para terapia gênica do sistema nervoso central, processo de obtenção e uso da mesma

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2722506B1 (fr) * 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations

Also Published As

Publication number Publication date
DE60030548T2 (de) 2007-10-04
EP1173224A1 (de) 2002-01-23
RU2242970C2 (ru) 2004-12-27
JP2002541125A (ja) 2002-12-03
DE60030548D1 (de) 2006-10-19
KR20010114237A (ko) 2001-12-31
CN1354678A (zh) 2002-06-19
NZ514415A (en) 2005-03-24
AU4372600A (en) 2000-10-23
IL145592A0 (en) 2002-06-30
CA2368185A1 (en) 2000-10-12
ZA200107888B (en) 2003-04-30
EP1173224B1 (de) 2006-09-06
KR100707711B1 (ko) 2007-04-16
WO2000059548A1 (en) 2000-10-12
AU770090B2 (en) 2004-02-12
EP1173224A4 (de) 2003-06-25

Similar Documents

Publication Publication Date Title
ATE338540T1 (de) Polyethyleneimine: dns-formulierungen für die aerosol-verabreichung
WO2000050050A8 (en) Multiparticulate formulation
WO2002060412A3 (en) Stabilised polymeric aerosols for pulmonary gene delivery
WO2003020949A3 (en) Targeted nucleic acid constructs and uses related thereto
WO2003084470A3 (en) Compositions and methods for targeted biological delivery of molecular carriers
WO2007008220A8 (en) Gene or drug delivery system
Cho et al. Folate receptor-mediated intracellular delivery of recombinant caspase-3 for inducing apoptosis
WO1999041402A3 (en) Targeting of genetic vaccine vectors
WO2005102431A3 (en) Aerosol delivery apparatus for pressure assisted breathing
MX2007012817A (es) Eliminacion de poblacion celular heterogenea o mezclada en tumores.
HK1004110A1 (en) Transfer of molecules into the cytosol of cells
AU2001294890A1 (en) Pei: dna vector formulations for in vitro and in vivo gene delivery
AUPR894201A0 (en) Respiratory delivery for gene therapy and lentiviral delivery particle
WO2008048234A3 (en) Inhaler system for targeted maximum drug-aerosol delivery
NZ526088A (en) Urea substituted imidazoquinoline ethers
MXPA05001607A (es) Forma galenica para suministro de ingredientes activos dirigido al colon.
WO1998051285A3 (en) Cationic amphiphile formulations
WO2001004135A3 (en) Crosslinked dna condensate compositions and gene delivery methods
WO2002078716A3 (en) Methylated promoters for intraductal treatment of breast cancer
WO2010040023A3 (en) Methods and compositions for protein delivery
WO2001094547A3 (en) Molecular delivery vehicle for delivery of selected compounds to targets
WO2004039957A3 (en) Inhibition of gene expression using rna interfering agents
ZA200205167B (en) gamma-IFN liquid-droplet aerosol and method.
AU2002217760A1 (en) Targeting drug/gene carriers to irradiated tissue
WO1998030709A3 (en) Non-immunogenic prodrugs and selectable markers for use in gene therapy

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties